Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1.
Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1.
复制标题
通过与保守蛋白NP，M1和NS1结合的疫苗接种来防止小鼠和禽流感A菌株。
DOI：
10.1111/j.1750-2659.2007.00010.x
复制
发表时间：
2007-03
影响因子：
4.4
通讯作者：
Shneider, Alexander M.
中科院分区：
文献类型：
--
作者：
Zhirnov, Oleg P.;Isaeva, Elena I.;Konakova, Tatyana E.;Thoidis, Galini;Piskareva, Lyudmila M.;Akopova, Irina I.;Kartashov, Alex;Altstein, Anatoly D.;Ilyinskii, Petr O.;Shneider, Alexander M.
背景 十多年来积累的实验数据表明，通过保守的流感蛋白免疫可以实现针对流感的跨毒株保护。与此同时，按照这些思路设计并涉及内部流感蛋白（主要是 NP 和 M1）的免疫方案的功效还不够。 目的 测试流感病毒NP、M1和NS1基因组合DNA疫苗的免疫原性和保护效果。 方法 在小鼠和鸡中测试 NP、M1 和 NS1 DNA 疫苗接种的免疫原性和保护效果。小鼠接受了针对小鼠的 H3N2 和 H5N2 病毒株的攻击，鸡则接受了禽 H5N3 病毒的攻击。 结果 在这些情况下，野生型 NS1 不会阻碍体内 NP/M1 免疫的细胞和体液反应。此外，在 NP/M1 免疫方案中添加 NS1 编码质粒可显着提高体内保护功效。 结论 将 NS1 添加到基于保守蛋白的流感免疫方案中是有希望的。通过对这些和其他保守的流感蛋白进行进一步的基因修饰，提供更高的安全性、表达和免疫原性，基于几种结构和非结构蛋白或其表位的重组疫苗将在多种物种中提供广泛的抗流感保护，这是可行的。
Background Experimental data accumulated over more than a decade indicate that cross‐strain protection against influenza may be achieved by immunization with conserved influenza proteins. At the same time, the efficacy of immunization schemes designed along these lines and involving internal influenza proteins, mostly NP and M1, has not been sufficient. Objective To test the immunogenicity and protective efficacy of DNA vaccination with a combination of NP, M1 and NS1 genes of influenza virus. Methods The immunogenicity and protective efficacy of DNA vaccination with NP, M1 and NS1 was tested in mice and chickens. Mice were challenged with mouse‐adapted viral strains H3N2 and H5N2 and chicken challenged with avian H5N3 virus. Results In these settings, wild‐type NS1 did not impede the cellular and humoral response to NP/M1 immunization in vivo. Moreover, addition of NS1‐encoding plasmid to the NP/M1 immunization protocol resulted in a significantly increased protective efficacy in vivo. Conclusions The addition of NS1 to an influenza immunization regimen based on conserved proteins bears promise. It is feasible that upon further genetic modification of these and additional conserved influenza proteins, providing for their higher safety, expression and immunogenicity, a recombinant vaccine based on several structural and non‐structural proteins or their epitopes will offer broad anti‐influenza protection in a wide range of species.
登录
查看更多内容
DOI：
10.1073/pnas.031575198
发表时间：
2001-02-27
影响因子：
11.1
作者：
Basler, CF;Reid, AH;Taubenberger, JK
通讯作者：
Taubenberger, JK
影响因子：
5.5
作者：
Chen, Z;Sahashi, Y;Tamura, S
通讯作者：
Tamura, S
影响因子：
32.4
作者：
Chen, WS;Antón, LC;Yewdell, JW
通讯作者：
Yewdell, JW
影响因子：
5.5
作者：
De Filette, M;Ramne, A;Fiers, W
通讯作者：
Fiers, W
影响因子：
5.4
作者：
Donelan, NR;Basler, CF;García-Sastre, A
通讯作者：
García-Sastre, A